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Abstract 
Purpose: Exercise for Health was a randomized, controlled trial designed to evaluate two 
modes of delivering (face-to-face [FtF] and over-the-telephone [Tel]) an 8-month 
translational exercise intervention, commencing 6-weeks post-breast cancer surgery (PS). 
Methods: Outcomes included quality of life (QoL), function (fitness and upper-body) and 
treatment-related side effects (fatigue, lymphoedema, body mass index, menopausal 
symptoms, anxiety, depression and pain).  Generalised estimating equation modelling 
determined time (baseline [5-weeks PS], mid-intervention [6-months PS], post-intervention 
[12-months PS]), group (FtF, Tel, Usual Care [UC]) and time-by-group effects. 194 women 
representative of the breast cancer population were randomised to the FtF (n=67), Tel (n=67) 
and UC (n=60) groups. Results: There were significant (p<0.05) interaction effects on QoL, 
fitness and fatigue, with differences being observed between the treatment groups and the UC 
group.  Trends observed for the treatment groups were similar. The treatment groups reported 
improved QoL, fitness and fatigue over time and changes observed between baseline and 
post-intervention were clinically relevant. In contrast, the UC group experienced no change, 
or worsening QoL, fitness and fatigue, mid-intervention.   Although improvements in the UC 
group occurred by 12-months post-surgery, the change did not meet the clinically relevant 
threshold. There were no differences in other treatment-related side-effects between groups.  
Conclusion: This translational intervention trial, delivered either face-to-face or over-the-
telephone, supports exercise as a form of adjuvant breast cancer therapy that can prevent 
declines in fitness and function during treatment and optimise recovery post-treatment.  
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Introduction 
With over one million women worldwide diagnosed with breast cancer each year, and 
improving survival rates,[1] there is an imperative for increased attention to breast cancer 
survivorship. Receiving treatment for breast cancer has long been associated with an array of 
physical and psychosocial consequences, with the type, prevalence and severity of concerns 
evolving with changes in the way breast cancer is treated.[2] Current estimates indicate that 
at 6-months post-diagnosis, 90% of women report at least one adverse treatment effect and 
60% report multiple sequelae, which influence function, the ability to adhere to adjuvant 
breast cancer treatment, quality of life (QoL) and potentially survival.[3] Notably, even 6-
years out from breast cancer, 30% of women report multiple, significant treatment-related 
sequelae that continue to influence longer-term morbidity and mortality.[3] Thus, there is a 
clear need for identifying strategies that can be integrated among current breast cancer care to 
optimize quality and quantity of survival. 
 
There exists a growing and compelling body of evidence supporting the benefits of exercise 
following the diagnosis of cancer, in particular breast cancer, with results summarized in 
meta-analyses and systematic reviews.[4-6] Exercise interventions implemented during 
and/or following treatment lead to improvements in cardiorespiratory fitness, body 
composition (i.e., muscle mass and bone health), immune function, strength and flexibility, 
body image, self-esteem and mood, and allow for better adjustment to illness. Exercise 
interventions have also been shown to reduce stress, depression, anxiety and the number and 
severity of side effects, including nausea, fatigue and pain. These benefits have been 
observed in exercise interventions involving aerobic- and/or resistance-based exercise 
undertaken for 90+ minutes per week.[6] Further, evidence from large cohort studies indicate 
that exercise may also improve survival,[7] with results supporting a dose-response 
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relationship whereby more exercise is better than less, but possibly only up to levels which 
meet national physical activity recommendations (150 minutes of moderate-intensity activity 
per week). 
 
To date, the majority of exercise intervention trials among women with breast cancer have 
evaluated supervised and clinic-based interventions, with eligibility criteria that restricts 
participation to those with early stage disease and no additional co-morbidities or 
complications that may interfere with participating in an exercise intervention.[4] While a 
limited number of trials have evaluated non-face-to-face intervention delivery methods,[8-16] 
effect of the exercise intervention on QoL, function and treatment-related side effects varies 
and none of these trials have compared the effect of different modes of delivery of the same 
exercise intervention. Thus, the current evidence base in support of exercise post-breast 
cancer largely pertains to the ‘healthier’ woman with breast cancer, who is able and willing to 
attend clinic-based exercise treatment. 
 
The call to include exercise as part of the standard of care provided to women following 
breast cancer is getting louder.[17] However, to change clinical practice, there is a clear need 
for comparative effectiveness trials demonstrating feasibility and effect of exercise associated 
with alternative delivery modalities. It is also necessary for benefits to be observed on a 
heterogeneous population of women with breast cancer, such that the intervention is suitable 
for all women, irrespective of health and disease status and participation needs to be feasible 
irrespective of place of residence. Exercise for Health (EfH) was a pragmatic trial designed to 
evaluate the feasibility and effect of an exercise intervention delivered either face-to-face or 
over-the-telephone, that if successful, could be integrated within clinical practice. The 8-
month intervention delivered via both modalities was designed to assist women during active 
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treatment periods (up to 6 months post-diagnosis), to more quickly and fully recover 
following treatment, and to develop the skills and confidence to become and stay physically 
active for the longer term. The purpose of this paper is to compare the effectiveness of the 
face-to-face and telephone-delivered exercise intervention on QoL, and patient-reported and 
clinically-measured function and treatment-related side effects. 
 
Methods 
The EfH trial (ACT RN: 012606000233527) was reviewed and approved by the Institutional 
Review Board (i.e., Ethics Committee) at the Queensland University of Technology and at 
each of the four participating hospitals. The analyses presented in this manuscript adhere to 
those outlined in the original grant application and presented in the baseline manuscript.[18] 
 
Patients 
A total of 194 women with a first diagnosis of invasive breast cancer were recruited into the 
‘Exercise for Health’ trial through four participating Brisbane (Australia) hospitals between 
October 2006 and June 2008. Breast cancer nurses introduced patients to the trial after their 
initial surgery. Interested patients were then contacted by research staff three to four weeks 
post-surgery to discuss the trial in detail and confirm informed consent. Women aged 20 to 
69 years, and residing within a 30 kilometre radius of the Brisbane central business district 
(to enable participation in face-to-face sessions) were eligible to participate. Exclusions were 
made for women who were pregnant or lactating, had plans for breast reconstructive surgery 
during the study period or with poor English. 
 
Study design  
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While a detailed explanation of trial methods and baseline participant characteristics have 
been published elsewhere,[18] key features of study design are summarised below. 
 
Timing of assessments and randomisation 
Disease and treatment characteristics were extracted from the Queensland Cancer Registry, 
including type of cancer, type of surgery, tumour size, cancer stage, lymph node status, while 
a self-reported questionnaire and battery of physical tests were implemented by Exercise 
Physiologists blinded to group allocation at pre-intervention/baseline (5.7 weeks post-
surgery, 95% CI: 5.2, 6.1 weeks); mid-intervention/6-months (25.6 weeks; 95% CI: 25.1, 
26.2 weeks) post-surgery and 8-weeks post-intervention /12 months (51.4 weeks; 95% CI: 
51.0, 51.9 weeks) post-surgery (Figure 1). The mid-intervention assessment coincides with 
mid to end of adjuvant treatment period and enables measurement of intervention effect on 
treatment-related symptoms at a time when they are expected to be at their highest.  The final 
data collection time point (approximately 2 months post-intervention) allows measurement of 
longer-term effect on outcomes and coincides with 12 months post-surgery, which is the time 
point when many of the outcomes have been previously shown to stabilise.[19-21] 
 
After baseline assessment, women were individually randomised into one of the three groups 
via a computer-generated, unblocked sequence of random numbers. Sixty-seven women were 
each randomised into the face-to-face-delivered exercise intervention group (FtF) and the 
telephone-delivered exercise intervention group (Tel), while sixty women were randomised 
into the usual-care group (UC). Figure 2 details the recruitment, randomisation and follow-up 
process. 
 
Intervention  
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For those in the FtF and Tel groups, the 8-month exercise intervention began in the week 
following baseline assessment (6 weeks post-surgery) (Figure 1). Key features of the 
intervention are presented in Table 1.  The intervention involved 16 scheduled sessions (in 
person or via telephone) with a designated Exercise Physiologist, starting weekly and 
tapering to monthly contacts after 4 months. Exercise prescription was Exercise Physiologist-
driven during the first third to half of the program and became more patient-driven over-time. 
This approach allowed patients to have their exercise prescription clinically-led during their 
active treatment period, when treatment-related symptoms were likely to be presenting and/or 
fluctuating and exercise confidence, skills and knowledge was at their lowest. The approach 
also acknowledges the need for longer-term behaviour change (beyond the treatment period), 
which would only occur if patients developed skills, knowledge and confidence to become 
and stay independent exercisers. At all stages of the intervention, women were progressing 
towards (or maintaining) the overall goal of exercising at least 4 days per week for 45 
minutes (accumulating 180+ minutes of exercise per week) and incorporating both aerobic 
and strength-based exercises (on at least 2 days per week). Exercise starting parameters and 
rate of progression was individually-tailored, taking into account existing level of fitness, 
presence of treatment-related side effects and exercise preferences. 
 
Usual care 
Women in the UC group were given no advice outside of that provided through usual care. 
This varied depending on treating clinician and/or hospital and may have included receipt of 
verbal or written encouragement for participating in physical activity during and beyond 
breast cancer, but with no formal or regular advice about what to do and how to do it. 
 
Outcomes of interest 
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Primary outcome: Quality of Life 
The primary outcome measure was QoL, as measured by the Functional Assessment of 
Cancer Therapy-Breast (FACT-B+4) questionnaire. This scale has been used widely in 
cancer research with high reliability and validity.[22, 23] The FACTB+4 includes 40 items 
rated on a five-point Likert scale ranging from 0 ‘not at all’ to 4 ‘very much’. This 
questionnaire includes the FACT-General (FACT-G),[24] consisting of four domains 
(physical, social, emotional, and functional well-being) and a breast cancer-specific subscale 
(FACT-B)[22] with an additional four questions specific to arm morbidity.[23] Scores were 
calculated according to the FACT manual,[25] resulting in total scores of 0-160, with higher 
scores representing better well-being. A priori sample size calculations indicated a minimum 
of 40 women per group was required to detect a clinically important difference of 8 units in 
overall QoL between groups or change over time (standard deviation of change in FACT-
B+4 over 12 months = 10 units),[22] with 90% power and 5% type I error (two tailed). 
 
Secondary Outcomes: patient-reported function and treatment-related symptoms 
Upper-body function and treatment-related symptoms including fatigue, menopausal 
symptoms (including psychological, anxiety, depression, somatic and vasomotor  scales) and 
neuropathic pain were measured by the Disabilities of the Arm, Shoulder and Hand 
Questionnaire (scale: 0-100, higher score denotes worse function),[26] the Functional 
Assessment of Chronic Illness Therapy – Fatigue Subscale (scale: 0-52, higher score denotes 
lower fatigue),[27] the Greene Climacteric Scale (scale 0-63, higher score denotes higher 
symptom presence)[28] and the Neuropathic Pain Scale (scale 0-100, higher score denotes 
higher pain,[29] respectively. The Greene Climacteric Scale was also used to evaluate anxiety 
and depression, with women reporting scores of >10 for scale items 1-6 and 7-11 (assessed 
separately) being classified as clinically anxious and clinically depressed, respectively. 
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Participants were also asked whether they had received a clinical diagnosis of lymphoedema, 
and if so, by whom and when. 
 
Secondary Outcomes: clinically measured function and treatment-related symptoms  
The 3-minute step test was used as a measure of aerobic fitness.[30] The step height was 
modified from 12 inches to 6 inches to accommodate knee and hip limitations of some of the 
participants (within-patient step height was standardised across all assessments). The 
metronome was set at 96 beats per minute and heart rate on test completion was used as the 
outcome measure. Lower heart rate indicates higher fitness. Upper-body strength and 
endurance was measured by an incremental exercise protocol combining a traditional upright 
row and shoulder press exercise using hand weights. Each stage lasted 20 seconds in duration 
and progression was made through number of repetitions and weight held. The prerequisite 
for advancement to the next stage was defined by maintaining correct form, range of motion 
and speed (as determined by the Exercise Physiologist). Stages ranged from 1 (no weight) 
through to 24 (3.5kg). The amount of weight held incremented by 0.5 kilograms after three 
completed stages, with 10 repetitions performed for each stage. The last successfully 
completed stage for each arm was recorded. This protocol has been successfully used in our 
prior work.[31] Lymphedema status was assessed using bioimpedance spectrophy (BIS), 
which is a previously well described objective method of subclinical and/or pitting 
lymphoedema.[32, 33] In brief, BIS measurements on each arm were carried out using an 
Imp SFB7 monitor (Impedimed, Brisbane, Australia). The impedance of the extracellular 
fluid for each limb was calculated using the manufacturer’s software. The ratio of impedance 
values, comparing the treated and untreated sides, was then calculated and converted into a 
lymphedema index (L-Dex) score. A participant was classified as having lymphedema when 
the L-Dex score was 10 or greater. Height was assessed at pre-intervention with the 
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participant barefoot and measured to the nearest 0.5 centimetres at baseline. Body weight 
(kg) was measured at all three assessments using analogue SecaTM scales. Weight was 
recorded to the nearest 0.5 kg. Weight and height were used to calculate body mass index 
(BMI) using the metric formula weight (kg) / height2 (m2) to produce a unit of measurement 
of kg·m-2. The Active Australia Survey was used to collect information on total minutes of 
walking and moderate and vigorous physical activity mid- and post-intervention.[34] 
 
Clinically relevant changes in outcomes 
Clinically relevant changes in outcome were determined a priori, with cut-offs identified 
previously by us or others. Specifically, a change of >8 quality of life units,[22] >5 fatigue 
units,[27] >1.5 stages for clinically measured upper-body function[31] and  >1 BMI unit 
(approximately 2.5kg change in body weight)[35] is clinically relevant with respect to 
perceived quality of life, fatigue, upper-body function and longer term health outcomes, 
respectively. Of note, these magnitudes of changes are equivalent to >½ standard deviation 
(sd) of baseline scores. As such, in the absence of previous work to guide clinically relevant 
cut-offs for our other outcomes of interest, a change of >½ sd of baseline scores was a priori 
deemed clinically relevant and was equivalent to a change of >8 beats/minute for fitness 
(heart rate) and >7.5, >7.5 and >9 units for upper-body function (self-report), menopausal 
symptoms and pain scores, respectively. 
 
Statistical Analysis  
Summary descriptive statistics for baseline characteristics included counts and percentages 
for categorical variables or means (standard deviations), alternatively medians (ranges), for 
continuously-scaled variables. Continuous outcomes were modelled using generalised 
estimating equations (GEE) to determine time (baseline, mid- and post-intervention) and 
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intervention group (FtF, Tel, UC) effects and the interaction between time and group. Means 
and 95% confidence intervals (CI) are reported for each estimate. GEEs were considered the 
most appropriate multivariate modelling technique, as unlike conventional repeated measures 
approaches, it is able to incorporate baseline data as well as all available data including those 
from participants with missing data over time. Intention-to-treat principles were applied to 
the analysis of data. No imputation was generated.  All analysis was undertaken using SPSS 
version 18 software (SPSS inc, Chicago, IL). 
 
Results 
Flow of participants through the trial has been reported in detail elsewhere[18] and is 
summarised in Figure 2. Briefly, of the 402 women who were approached about the trial, 318 
were deemed eligible and 194 women (61%) gave informed consent, completed the baseline 
assessment and were randomly allocated into one of the three trial groups (FtF n=67, Tel 
n=67, UC n=60). Reasons given for non-participation included had too many other 
commitments/were too busy, felt the program was not needed or were not coping. Trial 
participants were on average younger, but had similar disease characteristics to the 
Queensland breast cancer population (data not shown). The trial retention rate was 94% at 6 
months and 93% at 12 months. Women who withdrew (n=14) were similar in age, 
socioeconomic status and had similar disease characteristics compared to women who 
completed the trial and withdrawal rate did not differ by group allocation (6, 4, and 4 in the 
FtF, Tel and UC groups, respectively). 
 
Participant characteristics 
Median age of trial participants was 52 years (age range: 29-70 years). Personal and 
diagnostic characteristics, including body mass index, lymph node status, stage of disease and 
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receipt of adjuvant therapy were similar for participants in the FtF, Tel and UC groups (Table 
2). Women in the Tel group were more likely to be treated at a private hospital when 
compared with those in the UC group (61% and 50%, respectively) and less likely to have a 
mastectomy than the FtF and UC groups (22%, 39% and 43%, respectively). During the trial 
69% of women underwent chemotherapy, 71% underwent radiotherapy and 64% began 
hormone therapy. Type of adjuvant therapy was balanced between all three groups. 
 
Exercise trial adherence  
Information about adherence in the Exercise for Health trial has been previously 
reported.[18] On average, the FtF group participated in 88% (14 of 16) of their scheduled 
sessions with their Exercise Physiologist. Those in the Tel group participated in 81% (13 of 
16) of scheduled telephone calls. 
 
Quality of life  
The interaction effect between time and group was statistically significant (p=0.03) for QoL.  
The FtF and Tel exercise groups both reported increased QoL scores over time and by 12 
months post-treatment showed clinically higher QoL (>8 FACTB+4 units) compared with 
baseline scores (Table 2). In contrast, the UC group showed a delayed QoL recovery (no 
change between baseline and mid-intervention) and level of improvements observed by post-
intervention failed to meet the clinically relevant threshold. While the differences in change 
in QoL between baseline and mid-intervention, and baseline and post-intervention were 
similar for the FtF and Tel groups, only change in QoL for the Tel group differed 
significantly (p<0.05) compared with the UC groups (Table 3). 
 
Function, treatment-related side effects and physical activity levels 
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Change in function (specifically, aerobic fitness) and fatigue between groups and over time 
differed (p<0.05). The FtF and Tel groups reported improvements in fitness over-time, which 
were clinically relevant by post-intervention (>8 beats/minute heart rate declines) (Table 3). 
In contrast, the UC group reported worsening fitness at mid- and post-intervention and the 
differences between treatment groups and the UC in change in resting heart rate at mid- and 
post-intervention were significant (p<0.05).  Fatigue improved over-time for the treatment 
groups, with change between baseline and post-intervention fatigue scores being clinically 
relevant for the Tel group (Table 3).  In contrast, the UC group showed worsening fatigue 
between baseline and mid-intervention and improved fatigue between baseline and post-
intervention, although magnitude of change was neither statistically nor clinically relevant. 
 
Upper-body function and treatment-related side effects such as menopausal symptoms 
(including anxiety and depression) and pain improved over time (p<0.05) for all groups, and 
participating within the intervention did not influence the magnitude or rate of this change 
(Table 4). There was no difference between the mean body mass index and L-Dex measured 
at baseline, mid- and post-intervention for all groups (baseline BMI and L-Dex was 26.6+5.2 
and 1.1+6.8, respectively). There were no statistical or clinically relevant differences between 
groups over time for the proportion of women with lymphoedema, clinical anxiety, clinical 
depression or having had experienced BMI gains of >1 unit (Table 5). 
 
Of those in the FtF and Tel groups, 25% did not meet the intervention goal at mid- or post-
intervention and did not increase their total physical activity by 30+ minutes (a priori deemed 
clinically relevant) between baseline and mid- or post-intervention. There were also 66% of 
women in the UC group who participated in 180+ minutes of total weekly physical activity at 
6- or 12-months post-surgery and/or increased their level of activity by 30+ minutes 
15 
following baseline assessment. At 12-months post-surgery, median minutes of total physical 
activity and walking for exercise per week was 180 (0, 840), 120 (0, 1110) and 120 (0, 1120) 
and 90 (0, 480), 60 (0, 360) and 10 (0, 420) for those in the FtF, Tel and UC group, 
respectively. 
Discussion 
Exercise, when delivered using a pragmatic, translational approach and included as part of 
standard care provided to women with breast cancer, leads to significant benefits with respect 
to QoL, function and treatment-related side effects. Specifically, gains in QoL and fitness and 
declines in fatigue were observed for those in the exercise groups during and following breast 
cancer treatment and the benefits are similar irrespective of whether the exercise is delivered 
face-to-face or over-the-telephone.  In contrast, during the treatment period (between 6-weeks 
and 6-months post-surgery) those in the UC group experienced declines in fitness and no 
change in QoL and fatigue. Beyond the treatment period, although improvements in QoL, 
fatigue and fitness were observed, unlike the intervention groups the change for the UC group 
was of insufficient magnitude to be clinically relevant. 
 
An important and novel aspect of the EfH trial was the evaluation of two intervention 
delivery modes – face-to-face or telephone-delivered. The face-to-face delivery mode reflects 
the traditional approach used by Exercise Physiologists in the prescription of exercise, and at 
least in Australia there already exists public and private health reimbursement for use of such 
allied health services via this mode.  While the telephone-delivery of exercise prescription 
does not reflect standard practice, Cancer Councils throughout Australia commonly deliver 
support on a range of healthy behaviours via their telephone help-line, highlighting that the 
necessary infrastructure to deliver exercise prescription via this mode already exists. Also, 
delivering an exercise intervention using the telephone has the advantage of reaching all 
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women, irrespective of place of residence, and thus can accommodate the 30% of Australian 
women with breast cancer who live in rural, regional areas[36] and/or areas with limited 
access to specialist services. Further, the telephone-delivery of specialist services such as 
exercise has possible cost advantages compared to face-to-face delivery. Therefore, the 
evaluation of these two modes were purposely chosen as they reflect feasible delivery modes 
that could be integrated among standard practice quickly should the intervention prove 
effective.   While future analysis will specifically evaluate the cost-effectiveness of EfH 
delivered via the telephone or face-to-face, findings presented here highlight the similarities 
in effect size of the exercise intervention between the two modes of delivery. 
 
One of the many benefits associated with exercise following breast cancer is its potential to 
prevent treatment-related side effects particularly those associated with adjuvant therapy.[4] 
Participation in the EfH intervention prevented fatigue and declines in fitness, but did not 
seem to affect rates of lymphoedema, anxiety, depression or adverse changes in body mass 
index. There were also no differences observed in upper-body function, menopausal 
symptoms and pain between the groups. An active UC group (two-thirds were participating in 
180+ minutes of activity per week and/or increased activity levels by 30+ minutes between 
baseline and mid- or post-intervention) may have precluded differences being observed 
between groups for these specific outcomes. Alternatively, a higher exercise dose (25% of the 
exercise groups did not meet the intervention goal and did not increase their total physical 
activity levels by 30+ minutes between baseline and mid- or post-intervention) or different 
delivery setting (e.g., in a supervised, clinic-based setting) may be required to illicit 
prevention of these specific side effects. For prevention of gains in body mass index, exercise 
alone may not be sufficient and may require dietary changes as well. Alternatively, it is 
plausible that the outcome measures lack sensitivity to detect exercise-induced changes.  
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Nonetheless, EfH has clearly demonstrated women can feasibly participate in an exercise 
intervention delivered face-to-face or over-the-telephone, commencing 6-weeks post-surgery, 
and can do so safely, without exacerbating or initiating common treatment-related side 
effects. The intervention evaluated here included more frequent contact with women during 
the early phases of the program (weekly for 2 months and then fortnightly for 2 months) and 
tapering to monthly contact during the second half of the program. In an attempt to ensure 
optimal prevention of treatment-related side effects, future research may consider the 
evaluation of an intervention that tapers frequency of contact but also transitions from face-
to-face contact through to telephone-contact over the intervention period. This may also 
involve having a more flexible protocol with regard to contact between the Exercise 
Physiologist and patient, whereby when certain situations arise (e.g., no previous exercise 
history prior to participating in the intervention; change in treatment-related symptoms) 
contact increases to two-three times per week and tapers back when the participant’s exercise 
self-efficacy has improved. 
 
The strengths of this work relate to the recruitment of a sample generally representative of the 
wider breast cancer population, the evaluation of an exercise intervention that was delivered 
using a pragmatic approach to delivery suitable for translation into practice, assessors blinded 
to group allocation and application of intention to treat principles to analysis. However, there 
was a slight imbalance in numbers, place of treatment (public versus private hospital) and 
rates of mastectomy between groups following randomisation. While block randomisation 
may have led to better balance between groups, findings from adjusted analyses, which take 
into account rates of mastectomy and place of treatment, were no different to those presented 
within the manuscript. It is plausible that the EfH sample was more active at baseline 
compared with the wider breast cancer population, as is the case for the majority of exercise 
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intervention trials following cancer.[17] While we are unable to confirm this using data, it is 
important to note that the impact of such a bias on trial findings would be in the conservative 
direction, making it more difficult to establish a time and/or group effect. Consequently, 
demonstrating an intervention effect on QoL, function and fatigue using a translational 
intervention approach, is particularly compelling. 
 
In summary, findings from this study highlight that a translational exercise intervention 
implemented within 6-weeks post-breast cancer surgery is safe and effective at preventing 
fatigue and declines in fitness and optimising QoL, while our previous published findings 
highlight that the participation in the intervention is feasible[18]. Women were interested and 
able to integrate an additional form of adjuvant treatment into their standard breast cancer 
care, with exercise being particularly appealing since it is a form of treatment that they can 
control and that is associated with recovery benefits, including the potential to minimise 
adverse effects from their other forms of breast cancer treatment. Further, demonstrating that 
delivery of the intervention face-to-face or over-the-telephone has similar effect is a 
particularly novel and exciting finding with significant implications for the integration of 
exercise into the standard of breast cancer care provided to all women, irrespective of place 
of residence and access to specialist care. 
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Figure 1. Timeline indicating timing of assessments, randomisation and intervention  
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Figure 2. Flow chart of participant recruitment and retention 
 
 
 
Withdrew (n=12) 
Mid-intervention 
(six months post-surgery) 
n = 182 
Post-intervention 
(12 months post-surgery) 
n = 180 
Withdrew (n=2) 
Intention-to-treat  
n=194 
(Face-to-face, n=67; Telephone, n=67, Usual care, n=60) 
Enrollment 
(n = 200) 
Assessed for eligibility 
(n = 402) 
Excluded due to not meeting inclusion criteria (n = 84); 
Refused to participate (n = 108); Other reasons (n=10) 
Withdrew prior to baseline testing (n=6) 
Random allocation 
Baseline assessment 
Pre-intervention (five weeks post-surgery) 
n = 194 
Telephone (n = 67) Usual care (n = 60) Face-to-face (n = 67) 
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Table 1. Details of the 8-month exercise intervention 
Intervention Goal accumulating 180+ minutes of exercise per week, incorporating both aerobic and strength-based exercises  
Frequency 4+ times per week  
 All sessions included upper and lower-body range of motion exercises as part of warm-up and cool-down 
 
8-month intervention 
Type Intensity Duration/ 
session 
Frequency of sessions with 
Exercise Physiologist 
Responsibility of setting 
exercise prescription  
Weeks 1-4/month 1  Aerobic  Low to moderate 20-30 
minutes 
Once/week Exercise Physiologist  
Weeks 5-8/month 2 Aerobic with 
strength introduced 
Moderate 30-40 
minutes 
Once/week Exercise Physiologist 
Weeks 9-16/month 3-4 Aerobic and strength Moderate to high 45+ minutes Once/fortnight Shared between Exercise 
Physiologist and participant 
Weeks 17+/months 5-8 Aerobic and strength Moderate to high 45+ minutes Once/month Participant 
Progression and 
overload 
Manner (that is, modification of type, intensity, duration and responsibility of setting exercise prescription) and rate 
was individually-tailored with exercise history, exercise confidence, adherence to prescription for previous period and 
presence and severity of treatment-related side effects reflecting factors that influenced progression and overload. 
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Table 2. Baseline characteristics of study participants by group allocation (n=194) 
 
 Face-to-face group 
n=67 
Telephone group 
n=67 
Usual-care group 
n=60 
Age (years) 
mean (SD) 
 
51.2 (8.8) 
 
52.2 (8.6) 
 
53.9 (7.7) 
Body mass index (kg/m2) n (%) n (%) n (%) 
Underweight (<18.5) 
Healthy (18.5-24.9) 
Overweight (25-29.9) 
Obese (30+) 
1 (1.5) 
31 (46.3) 
22 (32.8) 
13 (19.4) 
1 (1.5) 
28 (41.8) 
19 (28.4) 
19 (28.4) 
3 (5.0) 
23 (38.3) 
22 (36.7) 
12 (20.0) 
Treating Hospital    
Private  36 (53.7) 41 (61.2) 30 (50.0) 
Public  31 (46.3) 26 (38.8) 30 (50.0) 
Lymph node status    
Negative 
Positive 
None removed 
Missing 
34  (50.7) 
29  (43.3) 
3  (4.5) 
1  (1.5) 
38  (56.7) 
29  (43.3) 
0  (0.0) 
- 
33  (55.0) 
23  (38.3) 
4  (6.7) 
- 
Stage    
0 
I 
II/III 
Unknown 
2 (3.0) 
23 (34.3) 
38 (56.7) 
4 (6.0) 
3 (4.5) 
18 (26.9) 
45 (67.2) 
1 (1.5) 
3 (5.0) 
18 (30.0) 
37 (61.7) 
2 (3.3) 
Tumour Size (mm)  
median (min, max) 
 
24.0 (6.0, 100.0) 
 
23.0 (0.1, 82.4) 
 
22.0 (2.2, 90.0) 
Type of Surgery    
Lumpectomy 
Mastectomy/MRM 
41 (61.2) 
26 (38.8) 
52 (77.6) 
15 (22.4) 
34 (56.7) 
26 (43.3) 
Chemotherapya     
Yes 
No 
41 (61.2) 
26 (38.8) 
42 (62.7) 
25 (37.3) 
34 (56.7) 
26 (43.3) 
Radiotherapya     
Yes 
No 
26 (38.8) 
41 (61.2) 
26 (38.8) 
41 (61.2) 
23 (38.3) 
37 (61.7) 
Hormone therapya     
Yes 
No 
42 (62.7) 
25 (37.3) 
38 (56.7) 
29 (43.3) 
34 (56.7) 
26 (43.3) 
Abbreviations: 
MRM: Modified-radical mastectomy; SD: standard deviation 
(a) Adjuvant therapy received over the 12-month study period 
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Table 3. Quality of life, function (fitness) and treatment-related side effects (fatigue) at pre-intervention (5 weeks), mid-intervention (6 months) 
and post-intervention (12 months) post-surgery 
 Pre-intervention  Mid-intervention  Post-intervention 
 
p-value ∆ mid-pre scores 
∆ post-pre scores 
 Mean (95% CI) 
 
Mean (95% CI) 
 
Mean (95% CI) 
 time x group 
interaction ∆ (95% CI)
 ∆ (95% CI) 
Quality of lifeb          0.030a   
 FtF 
 Tel 
 UC 
119.4 
112.1 
119.6 
(114.8, 123.9) 
(107.4, 116.8) 
(114.2, 125.0) 
 122.3 
120.5 
119.5 
(117.1, 127.6) 
(115.7, 125.2) 
(114.0, 124.9) 
 128.9 
125.6 
126.1 
(124.5, 133.4) 
(120.9, 130.2) 
(120.8, 131.4) 
  +2.9 (-1.2, 7.2) 
+8.4ef (4.8, 11.9) 
-0.1 (-4.0, 3.7) 
+9.5e (5.3.3.8) 
+13.5ef (10.0, 17.0) 
+6.5 (1.8, 11.1) 
Aerobic Fitnessc          0.016a   
FtF 
Tel 
UC 
124.0 
120.9 
115.2 
(120.3, 127.7) 
(116.4, 125.4) 
(111.0, 119.4) 
 119.7 
119.8 
121.0 
(115.6, 123.8) 
(115.5, 124.1) 
(115.5, 126.4) 
  115.0 
114.6 
117.9 
(111.0, 119.0) 
(111.0, 118.2) 
(112.6, 123.3) 
  -4.3f (-8.1, -0.6) 
-1.1f (-4.5, 2.2) 
+5.8 (-0.8, 11.6) 
-9.0ef (-12.9, -5.2) 
-6.3f (-10.2, -2.4) 
+2.7 (-3.0, 8.4) 
Fatigued        0.032a   
 FtF 
 Tel 
 UC 
36.8 
33.6 
37.2 
(34.3, 39.3) 
(30.7, 36.4) 
(34.1, 40.3) 
 37.7 
38.0 
36.0 
(34.8, 40.7) 
(35.5, 40.5) 
(33.2, 38.9) 
 41.7 
40.4 
41.8 
(39.2, 44.2) 
(38.0, 42.8) 
(39.2, 44.3) 
  +0.9f (-1.5, 3.3) 
+4.4f (1.8, 7.1) 
-1.2 (-3.9, 1.6) 
+4.9 (2.6, 7.2) 
+6.8e (3.9, 9.8) 
+4.6 (1.7, 7.4) 
(a) Statistically significant difference for time-effect p < 0.05. (b) Quality of life as measured by the FACTB+4 scale. Higher scores indicate better well-being (scale 
range: 0-160); change overtime or difference between groups >8 units is clinically important. (c) Aerobic fitness as assessed by heart rate on completion of modified 3-
minute step test. Lower heart rate indicates better fitness; change overtime or difference between groups >1/2 standard deviation (8 beats/minute) is clinically important. 
(d) Fatigue as measured by the FACIT-F Questionnaire. Lower scores indicate higher levels of fatigue (scale: 0-52); change overtime or difference between groups >5 
units is clinically important. (e) Clinically meaningful change over time. (f) p < 0.05 between groups compared to the usual-care group. Abbreviations: FtF: Face-to-face 
exercise group; Tel: Telephone exercise group; UC: Usual-care group. 
 
28 
Table 4. Effect of the exercise intervention on self-reported outcomes at pre-intervention (5 weeks), mid-intervention (6 months) and post-
intervention (12-months) post-surgery 
 Pre-intervention  Mid-intervention  Post-intervention 
 p-value 
 Mean (95% CI) 
 
Mean (95% CI) 
 
Mean (95% CI) 
 time x group 
interaction 
Menopause Symptomsc           
Psychological scale (0-33) 
 FtF 
 Tel 
 UC 
 
6.5 
7.5 
6.1 
 
(5.3, 7.8) 
(6.2, 8.8) 
(4.9, 7.4) 
  
6.3 
7.0 
7.0 
 
(5.0, 7.6) 
(5.5, 8.4) 
(5.7, 8.3) 
  
6.0 
6.1 
5.4 
 
(4.8, 7.2) 
(5.0, 7.2) 
(4.0, 6.9) 
 0.284a 
Somatic scale (0-21) 
 FtF 
 Tel 
 UC 
 
2.4 
3.0 
2.4 
 
(1.9, 3.0) 
(2.4, 3.7) 
(1.9, 2.9) 
  
3.3 
3.4 
3.1 
 
(2.6, 4.0) 
(2.6, 4.1) 
(2.3, 3.9) 
  
3.3 
3.1 
3.4 
 
(2.5, 4.0) 
(2.5, 3.7) 
(2.7, 4.1) 
 0.205a 
Vasomotor scale (0-6) 
 FtF 
 Tel 
 UC 
 
0.6 
1.3 
1.0 
 
(0.3, 0.9) 
(0.9, 1.7) 
(0.6, 1.4) 
  
2.2 
2.6 
1.9 
 
(1.7, 2.7) 
(2.1, 3.1) 
(1.4, 2.4) 
  
1.8 
2.4 
1.9 
 
(1.4, 2.3) 
(1.9, 2.9) 
(1.3, 2.4) 
 0.356ab 
Neuropathic paind (0-100)  
 FtF 
 Tel 
 UC 
 
18.0 
20.4 
18.1 
 
(13.8, 22.2) 
(16.0, 24.9) 
(13.6, 22.6) 
  
16.0 
12.3 
11.7 
 
(11.3, 20.7) 
(8.4, 16.1) 
(7.2, 16.1) 
  
13.0 
12.2 
11.4 
 
(8.7, 17.3) 
(8.2, 16.2) 
(7.4, 15.5) 
 0.441a 
Upper-body function, patient-reportede         0.056a 
 FtF 
 Tel 
 UC 
17.9 
24.5 
20.4 
(14.1, 21.7) 
(20.2, 28.8) 
(16.4, 24.3) 
 12.3 
12.3 
14.9 
(7.8, 16.7) 
(9.3, 15.3) 
(10.9, 18.8) 
 10.2 
11.0 
13.6 
(6.5, 14.0) 
(8.3, 13.7) 
(9.8, 17.4) 
  
Upper-body function, clinically measuredf        0.057ab 
FtF 
 Tel 
 UC 
7.3 
6.8 
6.3 
(6.7, 7.9) 
(6.1, 7.5) 
(5.4, 7.2) 
 8.9 
8.1 
6.9 
(8.2, 9.6) 
(7.4, 8.7) 
(6.0, 7.8) 
 9.2 
8.3 
8.0 
(8.6, 9.8) 
(7.8, 8.8) 
(7.1, 9.0) 
  
(a) Statistically significant difference for time-effect p < 0.05. (b) Statistically significant difference for group-effect p < 0.05. (c) 
Menopause symptoms as measured by the Greene Climacteric Scale. Higher scores indicate greater menopausal symptoms; change 
overtime or difference between groups >1/2 standard deviation (>7.5 units) is clinically important. (d) Neuropathic Pain Scale. Higher 
scores indicate higher levels of pain; change overtime or difference between groups >1/2 standard deviation (>9 units) is clinically 
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important. (e) Patient-reported upper-body function as measured by the DASH scale. Higher scores indicate worse function; change 
overtime or difference between groups >1/2 standard deviation (>7.5 units) is clinically important. (f) Clinically measured upper-body 
function as measured by strength and endurance test. Higher scores indicate better functioning; change overtime or difference between 
groups 1.5 stages is clinically important. Abbreviations: FtF: Face-to-face exercise group; Tel: Telephone exercise group; UC: Usual-care 
group. 
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Table 5. Proportion of women with lymphoedema, anxiety, depression and gains in 
body mass index at baseline, mid-intervention (6 months post-surgery) and post-
intervention (12 months post-surgery) 
 Baseline Mid-
intervention 
Post-
intervention 
 n (%) n (%) n (%) 
Lymphoedema       
  Self-report of a clinical diagnosis       
FtF 
 Tel 
 UC 
2 
1 
2 
(3.2) 
(1.5) 
(3.6) 
4 
6 
5 
(6.9) 
(10.3) 
(10.2) 
5 
2 
4 
(8.9) 
(3.3) 
(8.2) 
  Objectively-measureda       
FtF 
 Tel 
 UC 
1 
1 
0 
(1.5) 
(1.5) 
(0.0) 
4 
4 
6 
(6.5) 
(6.6) 
(10.7) 
8 
8 
9 
(13.1) 
(12.9) 
(16.4) 
Clinically anxiousb       
FtF 
 Tel 
 UC 
2 
2 
0 
(3.5) 
(3.4) 
(0.0) 
1 
5 
2 
(1.6) 
(8.3) 
(3.6) 
2 
2 
3 
(3.3) 
(3.3) 
(5.5) 
Clinically depressedc       
FtF 
 Tel 
 UC 
1 
2 
1 
(1.7) 
(3.4) 
(2.0) 
2 
4 
2 
(3.3) 
(6.6) 
(3.6) 
0 
0 
2 
(0.0) 
(0.0) 
(3.6) 
>1 body mass index unit change from baseline     
FtF 
 Tel 
 UC 
  13 
16 
13 
(21.0) 
(26.2) 
(24.1) 
11 
22 
13 
(18.0) 
(34.5) 
(24.1) 
(a) Objectively-measure lymphoedema as measured by BIS; a participant was 
classified as having lymphedema when the L-Dex score was >10. (b) Clinically 
anxious as measured by the Greene Climacteric Scale; women reporting scores of >10 
for scale items 1-6 were classified as clinically anxious. (c) Clinically depressed as 
measured by the Greene Climacteric Scale; women reporting scores of >10 for scale 
items 7-11 were classified as clinically depressed. Abbreviations: FtF: Face-to-face 
exercise group; Tel: Telephone exercise group; UC: Usual-care group. 
 
 
 
